Novo Nordisk A/S/€NOVOB

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.

Ticker

€NOVOB
Sector

Primary listing

XGAT

Employees

78,387

Headquarters

Bagsvaerd, Denmark

Novo Nordisk A/S Metrics

BasicAdvanced
€229B
15.36
€3.34
0.27
€1.56
3.04%

Bulls say / Bears say

Novo Nordisk’s semaglutide (Wegovy/Ozempic) has been recommended as a first-line obesity treatment by the European Association for the Study of Obesity, underscoring the company’s clinical leadership in GLP-1 therapies (Reuters).
The company is investing $1.09 billion to expand its Minas Gerais, Brazil facility, significantly increasing production capacity for injectable drugs like Ozempic and Wegovy to support global supply amid robust demand (Reuters).
Despite revising its 2025 outlook, Novo reported Q1 operating profit of DKK 38.79 billion, up 22 percent year-over-year and above analysts’ forecasts, highlighting resilient profitability amid market headwinds (Reuters).
A Reuters Breakingviews analysis warns that intensifying competition from over 140 obesity drugs in development could halve the combined market share of incumbent GLP-1 leaders, pressuring Novo’s valuation and growth prospects (Reuters).
The U.S. government’s 100 percent tariff on branded drug imports from October 1 threatens significant cost increases for Novo’s key products Ozempic and Wegovy, raising margin risks in its largest market (Reuters).
Novo Nordisk’s share of the European insulin market has fallen to roughly 45 percent, down from previous highs, as pricing pressure and competitor promotions erode its leading position outside North America (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy €NOVOB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs